NCT02015104View on ClinicalTrials.gov

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 18, 2013

Primary Completion Date

September 18, 2018

Study Completion Date

May 2, 2019

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))

TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis

BIOLOGICAL

PANVAC

A recombinant virus vector vaccine containing genes for human carcinoembryonic antigen (CEA), mucin-1 (MUC-1) and three co-stimulatory molecules (designated Triad of costimulatory molecules (TRICOM): B7.1, intercellular adhesion molecule-1 (ICAM-1), and leukocyte function-associated antigen-3 (LFA-3).

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

08901

Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

Rutgers Cancer Institute of New Jersey

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT02015104 - Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG | Biotech Hunter | Biotech Hunter